Home > Neurology > Eisai seeking accelerated FDA review of Alzheimer’s drug after U.S. coverage decision

Eisai seeking accelerated FDA review of Alzheimer’s drug after U.S. coverage decision


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Reuters - 08/04/2022 - Eisai Co Ltd on Friday said it still planned to seek an accelerated U.S. approval pathway for its experimental Alzheimer's drug even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.  On Thursday, after a months-long review and a pressure campaign from patient advocacy groups, the Centers for Medicare and Medicaid Services (CMS) said it would only pay for Biogen Inc's BIIB.O Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless they have demonstrated clear evidence of patient benefit.  Medicare covers nearly 64 million American...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on